AMGN Amgen
- 305.850
- +4.850+1.61%
- 305.700
- -0.150-0.05%
Amgen News
The Dow Dumped Exxon in 2020. Adding Salesforce Was a Losing Move.
The call, meant to make the benchmark better represent the economy, has left investors tracking the average with less money than they would have had otherwise.
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 8.86%. Currently, Amgen has a market capitalization of $161
Why the Dow's Topsy-Turvy May Isn't a Sign of a Broader Market Panic
Yes. the Dow has tumbled since topping 40,000. But it's mostly due to just a few stocks.
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
Are diet pills about to peak in the short term? This cartoon's predictions are probably more accurate than analysts
① In the US stock investment community, a saying called the “South Park” curse has been quietly circulating until now: any stock name that appears in the cartoon “South Park” will be sold off soon after; ② Now, the “South Park” spell has descended on the concept of diet pills.
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc's (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases.
AstraZeneca Touts PCSK9 Inhibitor in Lowering LDL Cholesterol When Added to Statin
Amgen (AMGN.US) rare blood disease treatment drug bkemv was approved by the FDA as an AstraZeneca Soliris generic
Zhitong Finance learned that the US Food and Drug Administration (FDA) approved Amgen (AMGN.US) drug Bkemv on Tuesday, the first biosimilar of Soliris, an AstraZeneca (AZN.US) drug to treat rare blood diseases. Amgen's drugs will be marketed under the Bkemv name. Biosimilars are replicas of complex biopharmaceuticals. According to the FDA, Bkemv is a replaceable biosimilar, which means it is highly similar to Soliris with no clinically significant differences.
Accelerated supply is expected to double the diet medicine market! Sales in 2033 are worth 150 billion US dollars
Experts expect global annual sales of diet pills to soar to around $150 billion by the early 2030s.
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval
By Ben Glickman Pharmaceutical regulators approved Amgen's Bkemv, a biosimilar to rare-disease treatment Soliris. The Food and Drug Administration said Tuesday that Bkemv, a monoclonal antibody, had
Nvidia, Advances in Cancer Research, Climate Change Under Trump: Market Domination
Express News | U.S. FDA: Amgen's Bkemv (Eculizumab-Aeeb) Comes With Boxed Warning
Express News | FDA: Amgen Inc's Bkemv (Eculizumab-Aeeb) Is Biosimilar to Soliris (Eculizumab)
Express News | U.S. FDA Approves Amgen Inc's Bkemv - Website
Tapping Into the GLP-1 Hype? Consider These Pharma Stocks.
Dow's 325-Point Fall Led By Losses For Merck, Amgen Stocks
This article was automatically generated by MarketWatch using technology from Automated Insights. The Dow Jones Industrial Average is trading down Tuesday afternoon with shares of Merck and Amgen fac
The diet medicine market is optimistic that sentiment is heating up, and the latest forecast is that the size will reach 150 billion US dollars
① Aikunwei wrote in a report this month that, driven by multiple factors, the global obesity drug market is expected to reach 131 billion US dollars by 2028; ② The BMO capital market also estimates that by 2033, annual sales of diet pills will reach 150 billion US dollars.
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
FDA Approves First Interchangeable Biosimilar for Two Rare Diseases
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; and the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. "Many rare conditions are life-threatening, and many do not have treatments," said Sarah Yim, director of the Office of Therapeutic Biologics and Biosimilars in the FDA's Center for Drug Eva...
US Stock GLP-1 Themed Fund Triggers Thinking: Who Will Be the Next “Novo Nordisk”?
① The GLP-1 themed fund listed last week not only allocates well-known US stocks such as Novo Nordisk and Eli Lilly, but also deals with Hong Kong stocks, Japanese stocks, and European stocks; ② ETF issuers believe that there is plenty of room for growth in the diet medicine market, which is enough for more companies to enter.
Analysis
Price Target
No Data
